Navigation Links
Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Dose-Ranging Field Study in Client-Owned Dogs with Osteoarthritis
Date:11/20/2013

; the potential for dilution if we sell shares of our common stock in future financings; the significant control over our business by our principal stockholders and management; the potential that a significant portion of our total outstanding shares could be sold into the market in the near future; effects of anti-takeover provisions in our charter documents and under Delaware law; and our intention not to pay dividends. These and other important factors discussed under the caption "Risk Factors" in the Company's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Contacts: 

Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664

Andrew Mielach (media)
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
2. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
3. Aratana Therapeutics to Report Second Quarter 2013 Financial Results
4. Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
5. Aratana Therapeutics Adds To Drug Development Team
6. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
7. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
8. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
9. Aratana Therapeutics Completes $15 Million Series B Financing
10. Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants
11. Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has ... now comes with a second treatment cup to help prevent ... new cup is thinner on the edges for a softer ... thin and uneven surfaces on the face, neck and décolleté. ... treatment on areas such as the cheeks and neck, or ...
(Date:7/10/2014)... PROVO, Utah , July 10, 2014 ... genome annotation and interpretation, today announced an ... sequencing (NGS) analytics for Lineagen,s NextStep Dx ... evaluation of neurodevelopmental and neurological disorders, currently ... chromosomal microarray (CMA) testing service used by ...
(Date:7/10/2014)... D.C., June 17, 2014 Using microscopic polymer ... specific gases, researchers at MIT,s Quantum Photonics Laboratory ... levels in the parts-per-billion range. Optical sensors are ... their high signal-to-noise ratio, compact, lightweight nature, and ... gas sensors had been developed before, the MIT ...
(Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Swell new sensors 2Even geckos can lose their grip 2
... Animal Model Shows Disease Progression Can Be Prevented, ... in the December issue of The European Journal of,Immunology ... of,studies made possible under a grant from the Alliance ... lupus-prone mice with a dual,inhibitor of TLR7 and TLR9 ...
... September 30, ... 2007, ... Bulletin Board: CKGT), a vertically integrated,grower, developer, manufacturer and marketer of a ... on November,19, 2007 and reported unaudited results for the period ended September ...
... Inc. (Amex:,SGN - News) has received FDA 510(k) ... its ambulatory event recorder throughout the United States.,This ... 200 HeartLife,Tempo Card, is a direct-to-consumer non-prescription flexible ... used as an early-detection,device by patients who desire ...
Cached Biology Technology:Dynavax Reports Progress in Lupus Program With Inhibitor of TLR7 and TLR9 2Dynavax Reports Progress in Lupus Program With Inhibitor of TLR7 and TLR9 3China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 2China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 3China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 4Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device 2Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device 3
(Date:7/11/2014)... set a "mouse TRAP" to capture the early signs ... published in the Journal of Clinical Investigation . ... TRAP to extract cellular and genetic information from a ... the Rockefeller Institute for Medical Research in 2008, TRAP ... or ribosomes, of the cell type of interest. Scientists ...
(Date:7/11/2014)... 2014---A team of researchers from The Chinese University of ... gene of wild soybean linked to salt tolerance, with ... saline soil. This study published online in Nature ... genomic information for crop improvement. , Soybean is an ... human selection, cultivated soybeans have less genetic diversities than ...
(Date:7/11/2014)... members to reduce aggression and gain access to scarce ... activities shows a certain pattern across the day. The ... Biology Letters . , Grooming between individuals in a ... To be groomed has hygienic benefits and is stress ... provide access to infants, mating opportunities and high quality ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Baboons groom early in the day to get benefits later 2
... The origin of the Tahitian vanilla orchid, whose cured fruit ... French Polynesian spice, has long eluded botanists. Known by the ... to exist only in cultivation; natural, wild populations of the ... team of investigators led by Pesach Lubinsky, a postdoctoral researcher ...
... purify the air when they are lit up by ... have discovered. Associate Professor Zhu Huai Yong, from ... glaziers in medieval forges were the first nanotechnologists who ... Professor Zhu said numerous church windows across Europe ...
... for capturing detailed images of the body,s anatomy. Thanks ... Mellon University scientist Eric Ahrens, MRI can be used ... of interest in the living body. The ability to ... will greatly aid the study and treatment of cancer, ...
Cached Biology News:Tahitian vanilla originated in Maya forests, says UC Riverside botanist 2Tahitian vanilla originated in Maya forests, says UC Riverside botanist 3Air-purifying church windows early nanotechnology 2Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 2Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 3